INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Public company

KALVKalVista Pharmaceuticals, Inc.

CIK 0001348911

EDGAR filingsOpen in network
Disclosed transactions58
Buys / sells0 / 9
Max Insider Score48
Connections7with evidence

KALV · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
55.0K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Sensenig BethanyDirector · Jun 11, 2026
  • ← Insider ofevidence
    Treanor PatrickDirector · Jun 11, 2026
  • ← Insider ofevidence
    Arif BilalChief Operations Officer · Jan 21, 2026
5
SN
Sweeny NicoleChief Commercial Officer
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D
—
40.0K sh
Jun 11, 2026
Jun 11, 2026
traded Jun 11, 2026
+0d
SEC FORM 4

Evidence

5
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
21.7K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

5
SN
Sweeny NicoleChief Commercial Officer
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
68.8K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

5
SN
Sweeny NicoleChief Commercial Officer
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
59.3K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

5
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
25.8K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

5
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
100.0K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

9
TP
Treanor PatrickDirector
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
10.0K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

9
TP
Treanor PatrickDirector
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
17.0K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

5
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
150.3K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

5
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
93.8K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

5
SN
Sweeny NicoleChief Commercial Officer
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
100.0K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

5
SN
Sweeny NicoleChief Commercial Officer
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
93.8K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

5
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
93.8K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

9
AB
Arif BilalChief Operations Officer
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
100.0K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

9
AB
Arif BilalChief Operations Officer
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
49.0K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

9
TP
Treanor PatrickDirector
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
10.0K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

9
TP
Treanor PatrickDirector
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
30.0K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

9
SB
Sensenig BethanyDirector
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
45.0K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

5
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
100.0K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

5
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
40.0K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

5
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
68.8K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

11
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
5,000 sh
May 22, 2026May 27, 2026
traded May 22, 2026
+5dSEC FORM 4

Evidence

15
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
5,000 sh
May 22, 2026May 27, 2026
traded May 22, 2026
+5dSEC FORM 4

Evidence

20
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Open-market sale
SELL$60K
2,239 sh
May 26, 2026May 27, 2026
traded May 26, 2026
+1dSEC FORM 4

Evidence

11
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
6,250 sh
May 21, 2026May 26, 2026
traded May 21, 2026
+5dSEC FORM 4

Evidence

20
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Open-market sale
SELL$72K
2,685 sh
May 22, 2026May 26, 2026
traded May 22, 2026
+4dSEC FORM 4

Evidence

15
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
6,250 sh
May 21, 2026May 26, 2026
traded May 21, 2026
+5dSEC FORM 4

Evidence

9
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
6,250 sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

31
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Open-market sale
SELL$38K
1,862 sh
Apr 17, 2026Apr 20, 2026
traded Apr 17, 2026
+3dSEC FORM 4

Evidence

5
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
6,250 sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

30
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Open-market sale
SELL$54K
2,686 sh
Apr 17, 2026Apr 20, 2026
traded Apr 17, 2026
+3dSEC FORM 4

Evidence

9
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
6,250 sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

9
SN
Sweeny NicoleChief Commercial Officer
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
6,250 sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

27
SN
Sweeny NicoleChief Commercial Officer
KALVKalVista Pharmaceuticals, Inc.
Open-market sale
SELL$38K
1,862 sh
Apr 17, 2026Apr 20, 2026
traded Apr 17, 2026
+3dSEC FORM 4

Evidence

9
SN
Sweeny NicoleChief Commercial Officer
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
6,250 sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

13
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
6,250 sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

11
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Grant or award
A—
100.0K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

15
AB
Arif BilalChief Operations Officer
KALVKalVista Pharmaceuticals, Inc.
Grant or award
A—
49.0K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

11
SN
Sweeny NicoleChief Commercial Officer
KALVKalVista Pharmaceuticals, Inc.
Grant or award
A—
100.0K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

11
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Grant or award
A—
100.0K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

23
SN
Sweeny NicoleChief Commercial Officer
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
5,000 sh
Nov 22, 2025Dec 4, 2025
traded Nov 22, 2025
+12dSEC FORM 4

Evidence

23
SN
Sweeny NicoleChief Commercial Officer
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
6,250 sh
Nov 21, 2025Dec 4, 2025
traded Nov 21, 2025
+13dSEC FORM 4

Evidence

23
SN
Sweeny NicoleChief Commercial Officer
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
5,000 sh
Nov 22, 2025Dec 4, 2025
traded Nov 22, 2025
+12dSEC FORM 4

Evidence

48
SN
Sweeny NicoleChief Commercial Officer
KALVKalVista Pharmaceuticals, Inc.
Open-market sale
SELL$51K
3,813 sh
Nov 24, 2025Dec 4, 2025
traded Nov 24, 2025
+10dSEC FORM 4

Evidence

23
SN
Sweeny NicoleChief Commercial Officer
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
6,250 sh
Nov 21, 2025Dec 4, 2025
traded Nov 21, 2025
+13dSEC FORM 4

Evidence

42
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Open-market sale
SELL$60K
4,471 sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence

15
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
5,000 sh
Nov 22, 2025Nov 26, 2025
traded Nov 22, 2025
+4dSEC FORM 4

Evidence

15
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
6,250 sh
Nov 21, 2025Nov 26, 2025
traded Nov 21, 2025
+5dSEC FORM 4

Evidence

30
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Open-market sale
SELL$71K
5,296 sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence

11
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
6,250 sh
Nov 21, 2025Nov 26, 2025
traded Nov 21, 2025
+5dSEC FORM 4

Evidence

11
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
5,000 sh
Nov 22, 2025Nov 26, 2025
traded Nov 22, 2025
+4dSEC FORM 4

Evidence

23
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
15.0K sh
Nov 21, 2025Nov 26, 2025
traded Nov 21, 2025
+5dSEC FORM 4

Evidence

15
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
15.0K sh
Nov 21, 2025Nov 26, 2025
traded Nov 21, 2025
+5dSEC FORM 4

Evidence

31
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Open-market sale
SELL$45K
3,075 sh
Nov 18, 2025Nov 19, 2025
traded Nov 18, 2025
+1dSEC FORM 4

Evidence

13
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
6,447 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

9
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
4,028 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

21
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
2,419 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

← Insider ofevidence
Sweeny Nicole
Chief Commercial Officer · Dec 4, 2025
  • ← Insider ofevidence
    Piekos BrianChief Financial Officer · Nov 26, 2025
  • ← Insider ofevidence
    Audhya Paul K.CHIEF MEDICAL OFFICER · Nov 19, 2025